Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

The Effect of taVNS and Upper GI Motility

2 juin 2026 mis à jour par: Daniel Keszthelyi

The Effect of Non-invasive Transauricular Vagus Nerve Stimulation on Upper Gastrointestinal Motility in Healthy Individuals

This single-center randomized controlled cross-over trial aims to investigate the effect of transcutaneous auricular vagus nerve stimulation on upper gastrointestinal motility in healthy individuals.

The primary aim of this study is to assess the impact of tVNS on gut motor function, with regards to its potential to induce phase III contractions in the upper GI tract.

Secondary objectives include:

  • To study the effect of tVNS on other parameters characterizing upper GI motility such as the number of duodenal phase III contractions, gastric and duodenal phase MMCs, amplitude of antral contractions and motility index
  • To study the effect of tVNS on plasma levels of motilin and PP
  • To evaluate the effect of tVNS on parameters related to autonomic outflow, using a Shimmer3 GSR Sensor for heart rate variability and skin conductance.
  • To compare the results of the measurements of antroduodenal manometry with measurements of Gastric Alimetry

Participants will undergo tVNS (applied to the cymba conchae of the left ear) alternating with sham stimulation (using a non-conducting electrode) in a blinded, pre-randomized fashion, using two 4-hour blocks during an 8-hour fasted antroduodenal manometry recording period. Optionally, participants may simultaneously also undergo body surface gastric mapping using the Gastric Alimetry system.

Aperçu de l'étude

Description détaillée

Visit 1 (screening visit) Following written informed consent, the medical history of each subject will be checked during a structured interview. A pregnancy will be excluded by a urine test (due to the use or fluoroscopy during insertion of the manometry catheter) and a 12-lead ECG will be performed at the end of the screening visit. The rationale for this is to ensure no evidence of cardiac conduction disorders and an additional safety step to ensure no cardiac dysrhythmic affect with tVNS use. All information obtained during the screening visit will be recorded in using an electronic CRF provided by Castor EDC, provided by the Clinical Trial Centre Maastricht (CTCM).

Visit 2 (test day) Participants will arrive after an overnight fast at the GI physiology unit of the Maastricht University Medical Center, where a trained and experienced nurse will insert an antroduodenal manometry catheter through the nose into the duodenum under fluoroscopy control and supervision of a gastroenterologist (as per routine clinical procedure). Using this catheter, stomach and duodenum motility patterns will be recorded for 8 hours. After the manometry is inserted, the tVNS device will be connected with an electrode which delivers stimulation transcutaneous in the outer ear. Participants will receive two types of stimulation (i.e. tVNS vs sham) in 2 blocks of 4 hours during the 8-hour registration period. The order of stimulation applied is randomized. Gastric phase III contractions generally occur every 90 minutes, so the 4-hour period is considered sufficient to detect two phase III contractions considered sufficient to detect the two phase III contractions.(10)

An iv catheter will be inserted to draw blood during the 8-hour registration period. Blood samples, each witch a maximum volume of 10 mL, will be taken every 30 minutes to measure motilin and PP as surrogate markers of vagal efferent influence on GI motor function. In addition, autonomic parameters will be registered during the entire test period, using a Shimmer3 GSR sensor. After the 8-hour test period, the manometry catheter, the electrodes of the tVNS device and the iv cannula are removed.

Additionally, participants may opt to take part in a body surface gastric mapping assessment. This non-invasive, electrophysiological measurement is performed using the Gastric Alimetry system, which involves placing a large adhesive patch with multiple electrodes on the upper abdomen. The system records gastric myoelectrical activity over time, providing insight into gastric motility patterns. The measurement is conducted concurrently with the manometry registration period.

Type d'étude

Interventionnel

Inscription (Estimé)

12

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Limburg
      • Maastricht, Limburg, Pays-Bas, 6229ER
        • Recrutement
        • Maastricht University

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte

Accepte les volontaires sains

Oui

La description

Inclusion Criteria:

  • Healthy participants (defined as those without a pre-existing medical comorbidity, including those without a history of cardiac arrhythmia).
  • Age between 18 and 55 years.
  • Ability to understand and speak the Dutch language.

Exclusion Criteria:

  • Pregnancy or lactation.
  • Use of any substances (such as medication or recreational drugs) influencing gastrointestinal motility
  • Not meeting the inclusion criteria above.
  • Students and employees of Maastricht University are not precluded from participation, unless they have a direct personal, professional of hierarchical position with regards to any of the study team members or their department.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Transcutaneous Auricular Vagal Nerve Stimulation
TaVNS
taVNS will be provided during a 4-hour block of the 8-hour fasted antroduodenal manometry recording period.
Comparateur placebo: Sham stimulation
Sham stimulation with a non-conducting electrode
Sham stimulation will be provided during a 4-hour block of the 8-hour fasted antroduodenal manometry recording period.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
A clinically meaningful increase in phase III contractions
Délai: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
A clinically meaningful increase in the number of phase III contractions of antral origin in the fasted period during the tVNS stimulation compared to the sham stimulation.
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
A clinically relevant increase in other upper GI motility parameters
Délai: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
A clinically relevant increase in other parameters characterizing upper GI motility such as the number of duodenal phase III contractions, gastric and duodenal phase MMCs, amplitude of antral contractions and motility index
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Concentration of plasma motilin and pancreatic polypeptide
Délai: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Changes in plasma motilin and pancreatic polypeptide following taVNS vs. sham stimulation
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Autonomic response: heart rate variability
Délai: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Changes in heart rate variability measured continuously using a Shimmer3 GSR sensor
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Electrodermal response: skin conductance
Délai: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Changes in skin conductance following taVNS vs sham stimulation, assessed continuously using a Shimmer3 GSR sensor.
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Agreement between gastric motility measurements obtained by antroduodenal manometry and Gastric Alimetry
Délai: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Agreement between antroduodenal manometry and Gastric Alimetry measurements obtained simultaneously.
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Daniel Keszthelyi, MD, PhD, Maastricht University Medical Center

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

25 février 2025

Achèvement primaire (Estimé)

1 juin 2026

Achèvement de l'étude (Estimé)

1 juin 2026

Dates d'inscription aux études

Première soumission

26 mai 2026

Première soumission répondant aux critères de contrôle qualité

2 juin 2026

Première publication (Réel)

8 juin 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

8 juin 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 juin 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner